Biocon Biologics looks to trim $300 million debt in 1 year

Biocon Biologics plans to reduce its acquisition debt by $300 million over the next year. The company recently refinanced $1.1 billion in debt, providing more financial flexibility. Biocon aims to capitalize on the growing insulin market, with plans to double its insulin production capacity in Malaysia.